@article{MTMT:34752035,
	title = {Accuracy of the Pancolonic Modified Mayo Score in predicting the long-term outcomes of ulcerative colitis: a promising scoring system},
	url = {https://m2.mtmt.hu/api/publication/34752035},
	author = {Bacsur, Péter and Wetwittayakhlang, Panu and Resál, Tamás and Földi, Emese and Vasas, Béla and Farkas, Bernadett and Rutka, Mariann and Bessissow, Talat and Afif, Waqqas and Bálint, Anita and Fábián, Anna and Bor, Renáta and Szepes, Zoltán and Farkas, Klaudia and Lakatos, Péter László and Molnár, Tamás},
	doi = {10.1177/17562848241239606},
	journal-iso = {THER ADV GASTROENTER},
	journal = {THERAPEUTIC ADVANCES IN GASTROENTEROLOGY},
	volume = {17},
	unique-id = {34752035},
	issn = {1756-283X},
	year = {2024},
	eissn = {1756-2848},
	orcid-numbers = {Bacsur, Péter/0000-0002-8534-0068; Wetwittayakhlang, Panu/0000-0002-5962-4112; Resál, Tamás/0000-0002-3842-9094; Rutka, Mariann/0000-0003-2360-7836; Bálint, Anita/0000-0002-3624-896X; Fábián, Anna/0000-0002-0824-7476; Bor, Renáta/0000-0001-9393-5240; Szepes, Zoltán/0000-0002-9466-8719; Farkas, Klaudia/0000-0003-0599-182X; Lakatos, Péter László/0000-0002-3948-6488; Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:34741931,
	title = {A fekélyes vastagbélgyulladás gyógyszeres és sebészeti kezelése},
	url = {https://m2.mtmt.hu/api/publication/34741931},
	author = {Miheller, Pál and Kristóf, Tünde and Bor, Renáta and Farkas, Klaudia and Golovics, Petra and Harsányi, László and Müller, Katalin Eszter and Milassin, Ágnes and Palatka, Károly and Schäfer, Eszter and Szamosi, Tamás and Sarlós, Patrícia and Molnár, Tamás},
	doi = {10.1556/650.2024.33050},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {165},
	unique-id = {34741931},
	issn = {0030-6002},
	year = {2024},
	eissn = {1788-6120},
	pages = {37-64},
	orcid-numbers = {Bor, Renáta/0000-0001-9393-5240; Farkas, Klaudia/0000-0003-0599-182X; Milassin, Ágnes/0000-0001-6902-8915; Sarlós, Patrícia/0000-0002-5086-9455; Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:34635367,
	title = {Szűrő kolonoszkópos vizsgálatok hatékonyságának és biztonságosságának értékelése a Szegedi Tudományegyetemen és a Bács-Kiskun Vármegyei Oktatókórházban 2019 és 2022 között [Analysis of efficacy and safety of colonoscopic screening program at the University of Szeged and the Bács-Kiskun County Teaching Hospital between 2019 and 2022]},
	url = {https://m2.mtmt.hu/api/publication/34635367},
	author = {Magyar, Dániel and Fábián, Anna and Vasas, Béla and Nacsev, Krisztián and Dubravcsik, Zsolt and Bősze, Zsófia and Tóth, Tibor and Bacsur, Péter and Bálint, Anita and Farkas, Klaudia and Molnár, Tamás and Resál, Tamás and Bor, Renáta and Szepes, Zoltán},
	doi = {10.1556/650.2024.32979},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {165},
	unique-id = {34635367},
	issn = {0030-6002},
	keywords = {colorectal cancer; colorectal adenoma; colorectal carcinoma; Polypectomy; vastagbélrák; colorectal screening program; colorectalis adenoma; colorectalis carcinoma; polypectomia; vastagbélszűrő program},
	year = {2024},
	eissn = {1788-6120},
	pages = {221-231},
	orcid-numbers = {Fábián, Anna/0000-0002-0824-7476; Bacsur, Péter/0000-0002-8534-0068; Bálint, Anita/0000-0002-3624-896X; Farkas, Klaudia/0000-0003-0599-182X; Molnár, Tamás/0000-0002-4913-7599; Resál, Tamás/0000-0002-3842-9094; Bor, Renáta/0000-0001-9393-5240; Szepes, Zoltán/0000-0002-9466-8719}
}

@article{MTMT:34546005,
	title = {P938 Effectiveness and safety of switching from original infliximab to GP1111 biosimilar in inflammatory bowel diseases – prospective, cohort study},
	url = {https://m2.mtmt.hu/api/publication/34546005},
	author = {Resál, Tamás and Bacsur, Péter and Pápista, M and Kata, D and Farkas, Bernadett and Bálint, Anita and Fábián, Anna and Bor, Renáta and Szepes, Zoltán and Farkas, Klaudia and Molnár, Tamás},
	doi = {10.1093/ecco-jcc/jjad212.1068},
	journal-iso = {J CROHNS COLITIS},
	journal = {JOURNAL OF CROHNS & COLITIS},
	volume = {18},
	unique-id = {34546005},
	issn = {1873-9946},
	year = {2024},
	eissn = {1876-4479},
	pages = {i1706-i1707},
	orcid-numbers = {Resál, Tamás/0000-0002-3842-9094; Bacsur, Péter/0000-0002-8534-0068; Bálint, Anita/0000-0002-3624-896X; Fábián, Anna/0000-0002-0824-7476; Bor, Renáta/0000-0001-9393-5240; Szepes, Zoltán/0000-0002-9466-8719; Farkas, Klaudia/0000-0003-0599-182X; Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:34538619,
	title = {P674 Real-world experiences of switching to subcutaneous formulation in IBD patients on maintenance vedolizumab treatment},
	url = {https://m2.mtmt.hu/api/publication/34538619},
	author = {Bacsur, Péter and Resál, Tamás and Farkas, Bernadett and Sarlós, P and Iliás, Á and Kata, Diána and Bálint, Anita and Fábián, Anna and Bor, Renáta and Szepes, Zoltán and Molnár, Tamás and Farkas, Klaudia},
	doi = {10.1093/ecco-jcc/jjad212.0804},
	journal-iso = {J CROHNS COLITIS},
	journal = {JOURNAL OF CROHNS & COLITIS},
	volume = {18},
	unique-id = {34538619},
	issn = {1873-9946},
	year = {2024},
	eissn = {1876-4479},
	pages = {i1279-i1280},
	orcid-numbers = {Bacsur, Péter/0000-0002-8534-0068; Resál, Tamás/0000-0002-3842-9094; Kata, Diána/0000-0002-4432-9380; Bálint, Anita/0000-0002-3624-896X; Fábián, Anna/0000-0002-0824-7476; Bor, Renáta/0000-0001-9393-5240; Szepes, Zoltán/0000-0002-9466-8719; Molnár, Tamás/0000-0002-4913-7599; Farkas, Klaudia/0000-0003-0599-182X}
}

@article{MTMT:34533257,
	title = {P356 Long-term outcome of UC patients in clinical remission with different level of mucosal activity: real world, retrospective, multicontinental study},
	url = {https://m2.mtmt.hu/api/publication/34533257},
	author = {Bacsur, Péter and Wetwittayakhlang, P and Resál, Tamás and Farkas, Bernadett and Rutka, Mariann and Bessissow, T and Afif, W and Bálint, Anita and Fábián, Anna and Bor, Renáta and Szepes, Zoltán and Farkas, Klaudia and Lakatos, Péter László and Molnár, Tamás},
	doi = {10.1093/ecco-jcc/jjad212.0486},
	journal-iso = {J CROHNS COLITIS},
	journal = {JOURNAL OF CROHNS & COLITIS},
	volume = {18},
	unique-id = {34533257},
	issn = {1873-9946},
	year = {2024},
	eissn = {1876-4479},
	pages = {i759-i760},
	orcid-numbers = {Bacsur, Péter/0000-0002-8534-0068; Resál, Tamás/0000-0002-3842-9094; Rutka, Mariann/0000-0003-2360-7836; Bálint, Anita/0000-0002-3624-896X; Fábián, Anna/0000-0002-0824-7476; Bor, Renáta/0000-0001-9393-5240; Szepes, Zoltán/0000-0002-9466-8719; Farkas, Klaudia/0000-0003-0599-182X; Lakatos, Péter László/0000-0002-3948-6488; Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:34509107,
	title = {Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab},
	url = {https://m2.mtmt.hu/api/publication/34509107},
	author = {Szemes, Kata and Borbásné Farkas, Kornélia and Sipos, Zoltán and Bor, Renáta and Fábián, Anna and Szepes, Zoltán and Farkas, Klaudia and Molnár, Tamás and Schafer, Eszter and Szamosi, Tamas and Salamon, Agnes and Vincze, Áron and Sarlós, Patrícia},
	doi = {10.3390/biomedicines12010158},
	journal-iso = {BIOMEDICINES},
	journal = {BIOMEDICINES},
	volume = {12},
	unique-id = {34509107},
	abstract = {Concomitant medications may alter the effect of biological therapy in inflammatory bowel disease. The aim was to investigate the effect of proton pump inhibitors on remission rates in patients with inflammatory bowel disease treated with the gut-selective vedolizumab. Patients from the Hungarian nationwide, multicenter vedolizumab cohort were selected for post hoc analysis. Primary outcomes were the assessment of clinical response and endoscopic and clinical remission at weeks 14 and 54. Secondary outcomes were the evaluation of the combined effect of concomitant steroid therapy and other factors, such as smoking, on remission. A total of 108 patients were identified with proton pump inhibitor data from 240 patients in the original cohort. Patients on steroids without proton pump inhibitors were more likely to have a clinical response at week 14 than patients on concomitant PPI (95% vs. 67%, p = 0.005). Non-smokers with IBD treated with VDZ were more likely to develop a clinical response at week 14 than smokers, particularly those not receiving PPI compared with patients on co-administered PPI therapy (81% vs. 53%, p = 0.041, and 92% vs. 74%, p = 0.029, respectively). We found that the use of PPIs in patients treated with VDZ may impair the achievement of response in certain subgroups. Unnecessary PPI prescriptions should be avoided.},
	year = {2024},
	eissn = {2227-9059},
	orcid-numbers = {Borbásné Farkas, Kornélia/0000-0002-5349-6527; Sipos, Zoltán/0000-0001-7845-8116; Bor, Renáta/0000-0001-9393-5240; Fábián, Anna/0000-0002-0824-7476; Szepes, Zoltán/0000-0002-9466-8719; Farkas, Klaudia/0000-0003-0599-182X; Molnár, Tamás/0000-0002-4913-7599; Vincze, Áron/0000-0003-2217-7686; Sarlós, Patrícia/0000-0002-5086-9455}
}

@article{MTMT:34133671,
	title = {Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease. Individual Participant Data Meta-Analysis of 309 patients from 12 studies},
	url = {https://m2.mtmt.hu/api/publication/34133671},
	author = {Huinink, Sebastiaan Ten Bokkel and Thomassen, Doranne and Steyerberg, Ewout W and Pauwels, Renske W M and Casanova, Maria J and Bouguen, Guillaume and Mak, Joyce W Y and Molnár, Tamás and Lobo, Alan J and Seidelin, Jacob B and Amiot, Aurelien and D'Haens, Geert and Rivière, Pauline and Guidi, Luisa and Bor, Renáta and Lin, Wei-Chen and Peyrin-Biroulet, Laurent and Gisbert, Javier P and van der Woude, C Janneke and de Vries, Annemarie C},
	doi = {10.1093/ecco-jcc/jjad118},
	journal-iso = {J CROHNS COLITIS},
	journal = {JOURNAL OF CROHNS & COLITIS},
	volume = {18},
	unique-id = {34133671},
	issn = {1873-9946},
	abstract = {The risk of relapse after anti-tumour necrosis factor [TNF] therapy discontinuation in Crohn's disease patients with perianal fistulas [pCD] is unclear. We aimed to assess this risk.A systematic literature search was conducted to identify cohort studies on the incidence of relapse following anti-TNF discontinuation in pCD patients. Individual Participant Data were requested from the original study cohorts. Inclusion criteria were age ≥16 years, pCD as (co)indication for start of anti-TNF therapy, >3 doses, and remission of luminal and pCD at anti-TNF discontinuation. Primary outcome was the cumulative incidence of CD relapse using Kaplan-Meier estimates. Secondary outcomes included response to retreatment and risk factors associated with relapse as assessed by Cox regression analysis.309 patients from 12 studies in 10 countries were included. Median duration of anti-TNF treatment was 14 months [IQR 5.8 - 32.5]. Most patients were treated for pCD without active luminal disease [89%], received first line anti-TNF therapy [87%] and continued immunomodulatory following anti-TNF discontinuation [78%]. Overall cumulative incidence of relapse was 36% [95% CI 25-48%] and 42% [95% CI 32-53%] at 1 and 2 years after anti-TNF discontinuation. Risk factors for relapse included smoking [HR 1.5 (1.0, 2.1)] and history of proctitis [HR 1.7 (1.1, 2.5)]. Overall retreatment response rate was 82%.This IPD-MA, on predominantly patients with pCD without active luminal disease and first line anti-TNF therapy, shows that over half of patients remain in remission 2 years after anti-TNF discontinuation. Therefore, anti-TNF discontinuation may be considered in this subgroup.},
	keywords = {Crohn's disease; ANTI-TNF THERAPY; discontinuation; Perianal fistulizing disease},
	year = {2024},
	eissn = {1876-4479},
	pages = {134-143},
	orcid-numbers = {Molnár, Tamás/0000-0002-4913-7599; Bor, Renáta/0000-0001-9393-5240}
}

@article{MTMT:34089134,
	title = {Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis. A Retrospective Worldwide Multicenter Collaborative Study},
	url = {https://m2.mtmt.hu/api/publication/34089134},
	author = {Resál, Tamás and Bacsur, Péter and Keresztes, Csilla and Bálint, Anita and Bor, Renáta and Fábián, Anna and Farkas, Bernadett and Katsanos, Kostas and Michalopoylos, George and Ribaldone, Davide Giuseppe and Attauabi, Mohamed and Zhao, Mirabella and Barak, Hadar Amir and Yanai, Henit and Bezzio, Cristina and Rispo, Antonio and Castiglione, Fabiana and Bar-Gil Shitrit, Ariella and Pugliese, Daniela and Armuzzi, Alessandro and Savarino, Edoardo Vincenzo and Kolar, Martin and Lukáš, Milan and Chashkova, Elena and Filip, Rafał and Rozieres, Aurore and Nancey, Stéphane and Krznarić, Željko and Schäfer, Eszter and Szamosi, A and Sarlós, Patrícia and Franko, Matej and Drobne, David and Knyazev, Oleg V and Kagramanova, Anna V and Limdi, Jimmy and Wetwittayakhlang, Panu and Lakatos, Péter László and Maharshak, Nitsan and Bannon, Lian and Nyári, Tibor András and Szepes, Zoltán and Farkas, Klaudia and Molnár, Tamás},
	doi = {10.1093/ibd/izad135},
	journal-iso = {INFLAMM BOWEL DIS},
	journal = {INFLAMMATORY BOWEL DISEASES},
	volume = {In press},
	unique-id = {34089134},
	issn = {1078-0998},
	abstract = {Tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB could be an option in the treatment of acute severe ulcerative colitis (ASUC). We aimed to investigate efficacy and safety of TFB in moderate-to-severe colitis and ASUC.This retrospective, international cohort study enrolling UC patients with ≥6-week follow-up period was conducted from February 1 to July 31, 2022. Indications were categorized as ASUC and chronic activity (CA). Baseline demographic and clinical data were obtained. Steroid-free remission (SFR), colectomy, and safety data were analyzed.A total of 391 UC patients (median age 38 [interquartile range, 28-47] years; follow-up period 26 [interquartile range, 14-52] weeks) were included. A total of 27.1% received TFB in ASUC. SFR rates were 23.7% (ASUC: 26.0%, CA: 22.8%) at week 12 and 41.1% (ASUC: 34.2%, CA: 43.5%) at week 52. The baseline partial Mayo score (odds ratio [OR], 0.850; P = .006) was negatively associated with week 12 SFR, while biologic-naïve patients (OR, 2.078; P = .04) more likely achieved week 52 SFR. The colectomy rate at week 52 was higher in ASUC group (17.6% vs 5.7%; P < .001) and decreased with age (OR, 0.94; P = .013). A total of 67 adverse events were reported, and 17.9% resulted in cessation of TFB. One case of thromboembolic event was reported.TFB is effective in both studied indications. TFB treatment resulted in high rates of SFR in the short and long terms. Higher baseline disease activity and previous biological therapies decreased efficacy. No new adverse event signals were found.},
	keywords = {Tofacitinib; acute severe ulcerative colitis; moderate-to severe ulcerative colitis},
	year = {2024},
	eissn = {1536-4844},
	orcid-numbers = {Resál, Tamás/0000-0002-3842-9094; Bacsur, Péter/0000-0002-8534-0068; Bálint, Anita/0000-0002-3624-896X; Bor, Renáta/0000-0001-9393-5240; Fábián, Anna/0000-0002-0824-7476; Sarlós, Patrícia/0000-0002-5086-9455; Lakatos, Péter László/0000-0002-3948-6488; Nyári, Tibor András/0000-0001-8900-6641; Szepes, Zoltán/0000-0002-9466-8719; Farkas, Klaudia/0000-0003-0599-182X; Molnár, Tamás/0000-0002-4913-7599}
}

@article{MTMT:34593738,
	title = {Real-life effectiveness of tofacitinib in two indications in ulcerative colitis: a retrospective worldwide, multicenter, collaborative study},
	url = {https://m2.mtmt.hu/api/publication/34593738},
	author = {Farkas, Klaudia and Resál, Tamás and Bacsur, Péter and Farkas, Bernadett and Bálint, Anita and Fábián, Anna and Bor, Renáta and A., Shitrit and D., Pugliese and D., Drobne and H., Yanai and T., Szamosi and M., Lukas and A., Kagramanova P.L. Lakatos and N., Maharshak and G., Michalopoulos and S., Nancey and Z., Krznaric and Szepes, Zoltán and Molnár, Tamás},
	journal-iso = {UEG JOURNAL},
	journal = {UNITED EUROPEAN GASTROENTEROLOGY JOURNAL},
	volume = {11},
	unique-id = {34593738},
	issn = {2050-6406},
	year = {2023},
	eissn = {2050-6414},
	pages = {202-202},
	orcid-numbers = {Farkas, Klaudia/0000-0003-0599-182X; Resál, Tamás/0000-0002-3842-9094; Bacsur, Péter/0000-0002-8534-0068; Bálint, Anita/0000-0002-3624-896X; Fábián, Anna/0000-0002-0824-7476; Bor, Renáta/0000-0001-9393-5240; Szepes, Zoltán/0000-0002-9466-8719; Molnár, Tamás/0000-0002-4913-7599}
}